
Clovis Oncology Inc
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company's clinical trial programs comprise three drug candidates designed to inhibit the growth of cancer tumors. Its lead product candidate is NDA 20-538 for metastatic adenocarcinoma of the pancreas; and other preclinical assets include NK-1 receptor antagonists for the treatment of inflammatory bowel disease; glio-selectins for the treatment of glioblastoma multiforme; and JTK inhibitors for multiple indications. Clovis Oncology markets its products through a limited direct sales force in the majority of its markets. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
Latest events on Quartr
Previous Events for Clovis Oncology Inc
Ticker
CLVS
Country
United States of America
About the company
https://clovisoncology.com/about/about-us/
Investor Relations page
https://ir.clovisoncology.com/investors-and-news/default.aspx